{"id":"W4230270945","doi":"10.1182/blood-2019-124116","title":"Brentuximab Vedotin with Chemotherapy for Stage 3/4 Classical Hodgkin Lymphoma (cHL): 4-Year Update of the Echelon-1 Study","year":2019,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"ABVD; Brentuximab vedotin; Medicine; Dacarbazine; Internal medicine; Vinblastine; Progression-free survival; Chemotherapy regimen; Clinical endpoint; Population; Oncology; Surgery; Procarbazine; Chemotherapy; Vincristine; Lymphoma; Randomized controlled trial; Hodgkin lymphoma; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01343329,0.0004572569,0.001849134,0.0004692873,0.0002349014,0.001466907,0.0007780322,0.0009638651,0.001507122],"category_scores_gemma":[0.004424858,0.000298427,0.001845831,0.0009203159,0.0003868723,0.001040953,0.0005680323,0.001746464,0.0002971092],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009772764,"about_ca_system_score_gemma":0.001213443,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008365007,"about_ca_topic_score_gemma":0.002115813,"domain_scores_codex":[0.9975804,0.001474799,0.0002346827,0.0001513427,0.0004076748,0.0001511657],"domain_scores_gemma":[0.9941128,0.002207812,0.001927215,0.0003999105,0.0006465687,0.0007057662],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2470056,0.004508303,0.1061287,0.006356934,0.01306631,0.000316056,0.0005810334,0.002461462,0.009043012,0.0009241591,0.01515133,0.594457],"study_design_scores_gemma":[0.2309507,0.154291,0.4178512,0.003601022,0.02743993,0.00149851,0.0003865903,0.002120496,0.00524526,0.001580744,0.1548683,0.0001661816],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7640041,0.2164728,0.001711684,0.004328621,0.0008619408,0.001394792,0.00392461,0.00009287695,0.007208481],"genre_scores_gemma":[0.9100773,0.06928378,0.002883127,0.005733758,0.001284636,0.001606105,0.006664369,0.00006336516,0.002403483],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01343329,"threshold_uncertainty_score":0.0710429,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008803946367613627,"score_gpt":0.2458218670917243,"score_spread":0.2370179207241107,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}